Synthego Stock

synthego.comHealthcareFounded: 2012Funding to Date: $415.07MM

Synthego, founded in 2012 by Paul and Michael Dabrowski, is a genome engineering company leveraging machine learning, automation, and gene editing to build platforms for science at scale. Synthego is setting out to accelerate CRISPR research, a genome engineering technique that could help cure genetic diseases or even bring back woolly mammoths from extinction. Synthego is headquartered in Redwood City, CA.

Register for Details

For more details on financing and valuation for Synthego, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Synthego.

Register Today

Team

Management Team

Paul Dabrowski
Co-Founder & Chief Executive Officer
John Tan
Chief Operating Officer & President
Avi Raval
Chief Financial Officer & Chief Business Officer
Robert Deans Ph.D
Chief Scientific Officer

Board Members

Drew Oetting
8VC
Francisco Gimenez Ph.D
8VC
Nathaniel Horwitz
RA Capital Management
Scott Nolan
Founders Fund

Other companies like Synthego in the Healthcare sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$809.52MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$396.01MM
Sector
Last Round Est. Valuation
$400.53MM
Sector
Last Round Est. Valuation
$1.53B

News

Synthego, a startup developing a platform for gene editing experiments, has raised an additional $100 million to advance its work.
Updated on: Jun 1, 2023